An observational study in COVID-19 (Coronavirus Disease 2019), sponsored by St. Martin De Porress Hospital. Recruiting at 2 sites in Taiwan. Per ClinicalTrials.gov, last updated 2026-10-30.
Sponsored by St. Martin De Porress Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 78 studies in COVID-19 with a site in Taiwan — 12 open to participants now, 13 under way, 7 of them phase 3. COVID-19 · Taiwan.
Among the 78 studies in COVID-19 with a site in Taiwan, this one is the 3rd largest by planned enrollment of the 22 observational ones that give a count, is the only one that started in 2026, is one of 22 observational ones, reaches primary completion later than 5 of the 12 other live ones, and was the 76th registered.
7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.
Browse COVID-19 studies →12 of the 78 studies in COVID-19 with a site in Taiwan are open now. Recruiting first, the newest first:
Pfizer · Sites in Taiwan, United States, Argentina and 15 more countries
Ages 18+
Pfizer · Sites in Taiwan, United States, Argentina and 16 more countries
Ages 12+
Merck Sharp & Dohme LLC · Sites in Taiwan, United States, Argentina and 21 more countries
Ages 18+
AstraZeneca · Sites in Taiwan, United States, Argentina and 36 more countries
Ages 18+
National Taiwan University Hospital · Sites in Taiwan
Ages up to 18 · Healthy volunteers
A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →
Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
78 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 17 · Phase 3 14 · Phase 4 3
First in 2019; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 15,000 is above the median of 268 across 3,209 observational studies indexed under COVID-19.
Median enrollment 137 across the 56 interventional studies, 465 across the 22 observational. Of the 55 that completed or were terminated, 9 (16%) have results posted.
This tab as a report to print or save as PDF → With an account.
34 of 78 have an industry lead sponsor. The 10 most frequent:
St. Martin De Porress Hospital is the lead sponsor of 11 studies on the registry; 4 are open to participants now.
St. Martin De Porress Hospital has 3 studies filed under COVID-19 — fewer than ten, so there is no comparison to draw.
4 of the studies in COVID-19 with a site in Taiwan that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07013474Phase 3PfizerA Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised | 2027-09-28 |
| NCT06679140Phase 3PfizerA Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease | 2027-10-01 |
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
| NCT07504341St. Martin De Porress HospitalPhysiological Finding in Management of COVID 19 Patients | 2027-03-11 |
Add all 4 to your calendar (.ics) → With an account.
Among the 78 studies in COVID-19 with a site in Taiwan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study utilizes physiological indicators of COVID-19 patients as tools for assessing, tracking, worsening, and improving the clinical symptoms of COVID-19 patients. This study employs simple and easy-to-use assessment methods, which can be further aided by artificial intelligence technology to facilitate early response and medication.
This study utilizes physiological indicators of COVID-19 patients, such as blood pressure, heart rate, respiratory rate, and level of consciousness, to develop Shock Index (SI), Mordified Shock Index (MSI), Age Shock Index (Age SI), Age Mordified Shock Index (Age MSI), and Respiratory Adjusted Shock Index (RASI), as well as other physiological indicators, as tools for assessing, tracking, worsening, and improving the clinical symptoms of COVID-19 patients. For patients with mild to severe illness, and in response to the shortage of manpower during a large influx of emergency patients, this study employs simple and easy-to-use assessment methods, which can be further aided by artificial intelligence technology to facilitate early response and medication.
The COVID-19 patient received treatment at the hospital between May 2022 and March 2027 from emergency room, OPD
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The COVID-19 patients were devided into admission ,OPD groups
Other: physiological parameters
systolic blood pressure, diastolic blood pressure , heart rate, respiratory rate , GCS
Shock index(SI) in the management of COVID -19
SI= heart rate / systolic blood pressre
Time frame: 2022 May to 2027 March
Mordified shock index(MSI) in the management of COVID -19
MSI=heart rate / mean arterial pressure
Time frame: 2022 May to 2027 March
Age shock index(Age SI) in the management of COVID -19
Age shock index =Age x (heart rate / systolic blood pression)
Time frame: 2022 May to 2027 March
Respiratory adjusted shock index (RASI) in the management of COVID-19
Respiratory adjusted shock index =(heart rate/systolic blood pression) x (repiratory rate/10)
Time frame: 2022 may to 2027 March
Plan to share: No — Under the privacy of patients the data of medical record can't be shared with others researchers.
No publications or documents are linked to this record.
Started Apr 2026 (actual). Primary completion is estimated for Mar 2027, 11 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
St. Martin De Porress Hospital